Commercial Debut of Coronado Industries' Pneumatic Trabeculoplasty Device at American Academy of Ophthalmology Meeting is Huge Success.

FOUNTAIN HILLS, Ariz. -- Coronado Industries (OTCBB: CDIK)

--Innovative Method for the Management of Glaucoma and Ocular Hypertension is Well Received

--Negotiations with New Distributors Advancing Faster Than Anticipated

Coronado Industries Inc. (OTCBB: CDIK), the manufacturers of unique proprietary pneumatic devices for the non-invasive treatment of glaucoma through its wholly owned subsidiary, Ophthalmic International, announced today that Pneumatic Trabeculoplasty was a huge success at this year's American Academy of Ophthalmology meeting for a number of reasons.

First of all, our retail booth, staffed by representatives of Coronado Industries, EuPharmed s.r.l. (our Italian distributor) and Izasa S.A. (our distributor in Spain and Portugal), experienced very high traffic and interest by the attending physicians. "It was exciting to see doctors from all over the world talking with staffers about where and how soon they could take delivery of our equipment," said Dr. Francesco Aspes, head of European Business for Coronado Industries.

Secondly, the management team of Coronado Industries had meetings with several companies interested in exclusive distribution rights for the United States market, and is moving forward with its negotiations at this time. "Though we can't go into great detail right now," said G. Richard Smith, CEO of Coronado Industries, "I can tell you that all negotiations include an up-front cash payment and acceptance of financial responsibility for the completion of our FDA requirements."

Last, and certainly not least, Coronado Industries' management team had meetings with EU companies interested in acquiring distribution rights for countries covered by our 2A approval but which do not currently have distribution contracts in place. "The rapid addition of additional distributors within the EU translates to substantial near-term revenue for the company," said Smith.

Dr. John W. Sharkey, president of Ophthalmic International, added that besides meeting with potential partners for Europe and the United States, companies from several other countries inquired about gaining distributorships for the PNT device. "Obviously we will follow up on these inquiries and where we can utilize our CE file to achieve a rapid registration we will move quickly to do so."

"This has been a very exciting meeting," stated Smith. "We certainly owe our success to the work of Drs. Sharkey and Aspes over the last 16 months. They have dramatically impacted our company. They have completed our 2A registration and started the marketing of our product outside of the United States, establishing cash flow from sales. They have been instrumental in raising the awareness of PNT as a medical procedure and as a viable product. They have elevated our company to a level of professionalism that we can all be proud of. Best yet," Smith went on to say, "is that they aren't even close to being done yet."

Profitability from outside sales is expected next year and a solid plan for the completion of our FDA approval process is in place.

Coronado Industries through its wholly owned subsidiary, Ophthalmic International, is focused on the development and commercialization of its patented procedure as a cost-effective alternative for the treatment of the most common types of glaucoma which are open angle and pigmentary as well as for the treatment of ocular hypertension.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.